S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

BACKGROUND: This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer. METHODS: Patients received AC every 3 weeks for four cycles followed by S-1...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Moon, Yong Wha, Lee, Soohyeon, Park, Byeong-Woo, Kim, Eun-Kyung, Kim, Seung Il, Koo, Ja Seung, Park, Seho, Kim, Min Jung, Chung, Hyun Cheol, Kim, Joo-Hang, Sohn, Joohyuk
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4029391/
https://ncbi.nlm.nih.gov/pubmed/24314307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-583
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items